门冬胰岛素30注射液治疗初诊2型糖尿病50例

BIAsp30 for Treating 50 Cases of Primary Diagnosed Type 2 Diabetes

目的观察门冬胰岛素30注射液(诺和锐30)对初诊2型糖尿病的血糖控制效果。方法对2008年5月至11月住院和门诊初诊患者50例进行12周的诺和锐30治疗,观察空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1C)、空腹C肽(F-C)、空腹胰岛素(FNS)、餐后2hC肽(2h-C)、餐后2h胰岛素(2h-NS)的变化及不良反应。结果治疗12周后,FPG,2hPG,HbA1C水平均较治疗前明显下降(P<0.01),F-C,FNS,2h-C,2h-NS均较治疗前明显升高(P<0.01),无严重低血糖事件及其他严重不良反应。结论诺和锐30是一种可有效降低2型糖尿病患者空腹及餐后血糖的预混胰岛素剂型。

Objective To investigate the effect of BIAsp30 on controlling blood glucose level in the patients with primary diagnosed type 2 diabetes. Methods 50 inpatients and outpatients with first diagnosed type 2 diabetes in our hospital from May to November 2008 were treated with BIAsp30 for 12 weeks. The changes of fasting plasma glueose（FPG）, 2 h postprandial plasma glucose（2 h PG）, glyeosylated hemoglobin（HbA1c）, fasting peptide - C（F - C）, fasting insnlin（FNS）, 2 h - C, 2 h - NS and adverse reactions were observed. Results After 12 weeks treatment, FPG and 2 h PG were obviously reduced compared with before treatment（ P 〈0.01）. F- C, FNS, 2 h- C and 2 h-NS were remarkably increased compared with before treatment（P〈 0.01）. No severe hypoglycemic events and other adverse reactions occurred. Conclusion BIAsp30 is an effective and safe premixed insulin preparation for treating type 2 diabetes, which can effectively reduce fasting glucose and postprandial glucose.